Cypress Bioscience - Best Pharma Stocks of 2007

Company: Cypress Bioscience
Starting stock price: $7.64
Ending stock price: $11.03
Percent Change: 44.37%

Details: Last year Cypress Bioscience marked several big milestones. On May 22, the company wrapped up a second Phase III trial of its drug candidate milnacipran, a dual-reuptake inhibitor that acts on norepinephrine and serotonin. The company is trying to commercialize it for use against fibromyalgia. Then, May 31, Cypress launched a public offering of 4.7 million shares.

Cypress then presented the results to the American College of Rheumatology in November: Milnacipran delivered “statistically significant and clinically meaningful improvements in both pain and other core symptoms associated with fibromyalgia,” the company announced. By year’s end, the company and its development partner Forrest Laboratories submitted a new drug application with the FDA. The compound already is approved for use in more than 50 countries.

Cypress Bioscience - Best Pharma Stocks of 2007

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.